![]() |
Name |
Dihydroramulosin
|
Molecular Formula | C10H16O3 | |
IUPAC Name* |
(3R,4aS,8S,8aR)-8-hydroxy-3-methyl-3,4,4a,5,6,7,8,8a-octahydroisochromen-1-one
|
|
SMILES |
C[C@@H]1C[C@@H]2CCC[C@@H]([C@@H]2C(=O)O1)O
|
|
InChI |
InChI=1S/C10H16O3/c1-6-5-7-3-2-4-8(11)9(7)10(12)13-6/h6-9,11H,2-5H2,1H3/t6-,7+,8+,9-/m1/s1
|
|
InChIKey |
MXMDZXIALPKANE-RYPBNFRJSA-N
|
|
Synonyms |
Dihydroramulosin; (3R,4aS,8S,8aR)-8-hydroxy-3-rnethyl-3,4,4a,5,6,7,8,8a-octahydro-1H-2-benzopyran-1-one
|
|
CAS | NA | |
PubChem CID | 10535485 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 184.23 | ALogp: | 1.3 |
HBD: | 1 | HBA: | 3 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 46.5 | Aromatic Rings: | 2 |
Heavy Atoms: | 13 | QED Weighted: | 0.581 |
Caco-2 Permeability: | -4.546 | MDCK Permeability: | 0.00010727 |
Pgp-inhibitor: | 0.005 | Pgp-substrate: | 0.038 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.016 |
30% Bioavailability (F30%): | 0.977 |
Blood-Brain-Barrier Penetration (BBB): | 0.527 | Plasma Protein Binding (PPB): | 21.12% |
Volume Distribution (VD): | 1.04 | Fu: | 68.35% |
CYP1A2-inhibitor: | 0.196 | CYP1A2-substrate: | 0.196 |
CYP2C19-inhibitor: | 0.032 | CYP2C19-substrate: | 0.687 |
CYP2C9-inhibitor: | 0.013 | CYP2C9-substrate: | 0.386 |
CYP2D6-inhibitor: | 0.004 | CYP2D6-substrate: | 0.489 |
CYP3A4-inhibitor: | 0.04 | CYP3A4-substrate: | 0.248 |
Clearance (CL): | 9.675 | Half-life (T1/2): | 0.436 |
hERG Blockers: | 0.022 | Human Hepatotoxicity (H-HT): | 0.238 |
Drug-inuced Liver Injury (DILI): | 0.575 | AMES Toxicity: | 0.087 |
Rat Oral Acute Toxicity: | 0.054 | Maximum Recommended Daily Dose: | 0.225 |
Skin Sensitization: | 0.877 | Carcinogencity: | 0.768 |
Eye Corrosion: | 0.953 | Eye Irritation: | 0.972 |
Respiratory Toxicity: | 0.757 |